Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03465891 | Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT03512353 | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | terminated | Phase 2 | 7 | AmgenINDUSTRY | 1 | Jan 8, 2021 |
| clinicaltrials |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | terminated | Phase 1 / Phase 2 | 25 | Acerta Pharma BVINDUSTRY | 2 | Jan 6, 2021 | clinicaltrials |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | terminated | Phase 2 | 24 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML | terminated | Phase 2 | 3 | Milton S. Hershey Medical CenterOTHER | 1 | Dec 16, 2020 | clinicaltrials |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients(TXA127-PBSC) | terminated | Phase 2 | 75 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide | terminated | Phase 2 | 10 | PharmaMarINDUSTRY | 3 | Dec 2, 2020 | clinicaltrials |
| NCT02151903 | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL | terminated | Phase 1 / Phase 2 | 5 | Alopexx Oncology, LLCINDUSTRY | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01874288 | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL(DI-Leu16-IL2) | terminated | Phase 1 / Phase 2 | 24 | Alopexx Oncology, LLCINDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | terminated | Phase 2 | 326 | Gilead SciencesINDUSTRY | 2 | Nov 19, 2020 | clinicaltrials |
| NCT03837457 | PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study(PRISM) | terminated | Phase 2 | 8 | miRagen Therapeutics, Inc.INDUSTRY | 3 | Nov 19, 2020 | clinicaltrials |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma(IFM2014-03) | terminated | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma(AMETHYST) | terminated | Phase 1 / Phase 2 | 7 | Enceladus Pharmaceuticals BVINDUSTRY | 0 | Nov 6, 2020 | clinicaltrials |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | terminated | Phase 1 / Phase 2 | 15 | PrECOG, LLC.OTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02937675 | A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 28 | Effector TherapeuticsINDUSTRY | 1 | Nov 2, 2020 | clinicaltrials |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Oct 27, 2020 | clinicaltrials |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | terminated | Phase 1 / Phase 2 | 12 | Autolus LimitedINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01498445 | An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) | terminated | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | terminated | Phase 1 / Phase 2 | 39 | Sunesis PharmaceuticalsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03070964 | A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma | terminated | Phase 2 | 14 | PharmaMarINDUSTRY | 4 | Oct 14, 2020 | clinicaltrials |
| NCT00020969 | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 2 | — | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 7 | Oct 1, 2020 | clinicaltrials |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT00506948 | Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT02952573 | Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement | terminated | Phase 2 | 20 | University Health Network, TorontoOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT02266147 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 29 | Dynavax Technologies CorporationINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | terminated | Phase 1 / Phase 2 | 25 | The Lymphoma Academic Research OrganisationOTHER | 2 | Sep 2, 2020 | clinicaltrials |
| NCT01038856 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera(OSI-TAR-766) | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT00914940 | Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | terminated | Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT02767934 | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 2 | 12 | University of WashingtonOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT02875067 | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT00983528 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | University of California, San DiegoOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT02730884 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 65 | AmgenINDUSTRY | 2 | Jul 13, 2020 | clinicaltrials |
| NCT03265717 | DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia | terminated | Phase 2 | 26 | InvectysINDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | terminated | Phase 1 / Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 5 | Mayo ClinicOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | terminated | Phase 2 | 66 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | terminated | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | Ajai ChariOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 37 | St. Jude Children's Research HospitalOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT02624986 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | terminated | Phase 1 / Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 5 | May 18, 2020 | clinicaltrials |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | terminated | Phase 2 | 342 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT02906696 | Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT02535364 | Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)(ROCKET) | terminated | Phase 2 | 82 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | May 4, 2020 | clinicaltrials |
| NCT00632827 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) | terminated | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Apr 21, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 12, 2021source: clinicaltrials